Following the news that the Indian state of Maharashtra has fixed the price of remdesivir;
Prashant Khadayate, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view:
“Maharashtra is the worst affected state of the COVID-19 outbreak in India. The state has reported more than 1.55 million confirmed cases and 41,196 deaths as of 16 October 2020, the highest in the country. Against this backdrop, Maharashtra has become the first state in India to fix the price of remdesivir at Rs 2,360 ($32.17), which is 16 per cent more economical than the cheapest brand Remdac at Rs 2,800 ($38.19) by Zydus Cadila in the Indian market and 56 per cent more economical compared to the highest-priced brand Covifor at Rs 5,400 ($73.64) by Hetero Labs.
“In August 2020, GlobalData suggested that remdesivir price regulation is required to safeguard patients’ interest in India and remdesivir prices should be made as affordable as possible, in the best interest of patients and healthcare providers.
“The move to fix price is unique as drugs’ price deemed crucial for the treatment mainly falls in the purview of the Drug Price Control Order (DPCO), which is controlled by the central government. Since the Maharashtra government has passed this order, DPCO did not play any role in curbing remdesivir’s prices. However, DPCO should follow and recommend price cuts across all the states.
“The decision by Maharashtra should be appreciated as COVID-19 is going to remain a public health problem for a very long time. Moreover, as experts already cautioned that the COVID-19 pandemic may last until the end of 2021, such price fixation decisions should be taken by the Indian government as well.”
Following the release of the WHO report about not getting any significant advantage with Remdesivir and HCQ in terms of either survival or hospital stay the demand will fall rapidly. Soon it will sell at 1100 or less